Illumina, Inc. (0J8Z.L)
USD 72.92
(-4.74%)
USD 72.92
(-4.74%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.36 Billion USD | -22.77% |
| 2022 | 5.65 Billion USD | 26.27% |
| 2021 | 4.47 Billion USD | 54.86% |
| 2020 | 2.89 Billion USD | 6.96% |
| 2019 | 2.7 Billion USD | -13.2% |
| 2018 | 3.11 Billion USD | 29.05% |
| 2017 | 2.41 Billion USD | 20.03% |
| 2016 | 2.01 Billion USD | 9.31% |
| 2015 | 1.83 Billion USD | -1.89% |
| 2014 | 1.87 Billion USD | 26.17% |
| 2013 | 1.48 Billion USD | 19.1% |
| 2012 | 1.24 Billion USD | 11.32% |
| 2011 | 1.12 Billion USD | 74.71% |
| 2010 | 641.43 Million USD | 13.39% |
| 2009 | 565.68 Million USD | 7.04% |
| 2008 | 528.5 Million USD | -8.25% |
| 2007 | 576.05 Million USD | 981.95% |
| 2006 | 53.24 Million USD | 89.39% |
| 2005 | 28.11 Million USD | 24.15% |
| 2004 | 22.64 Million USD | -56.32% |
| 2003 | 51.84 Million USD | 3.36% |
| 2002 | 50.16 Million USD | 220.03% |
| 2001 | 15.67 Million USD | 80.31% |
| 2000 | 8.69 Million USD | 366.76% |
| 1999 | 1.86 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 4.3 Billion USD | -1.37% |
| 2024 Q3 | 3.57 Billion USD | -16.28% |
| 2024 Q2 | 4.64 Billion USD | 7.87% |
| 2023 Q4 | 4.36 Billion USD | 3.36% |
| 2023 Q3 | 4.22 Billion USD | -19.06% |
| 2023 FY | 4.36 Billion USD | -22.77% |
| 2023 Q1 | 5.11 Billion USD | -9.46% |
| 2023 Q2 | 5.21 Billion USD | 1.97% |
| 2022 Q3 | 4.52 Billion USD | -9.57% |
| 2022 Q4 | 5.65 Billion USD | 24.93% |
| 2022 FY | 5.65 Billion USD | 26.27% |
| 2022 Q1 | 4.37 Billion USD | -2.19% |
| 2022 Q2 | 5 Billion USD | 14.27% |
| 2021 Q2 | 3.49 Billion USD | -8.82% |
| 2021 FY | 4.47 Billion USD | 54.86% |
| 2021 Q1 | 3.83 Billion USD | 32.58% |
| 2021 Q4 | 4.47 Billion USD | 0.16% |
| 2021 Q3 | 4.47 Billion USD | 27.9% |
| 2020 FY | 2.89 Billion USD | 6.96% |
| 2020 Q1 | 2.62 Billion USD | -2.85% |
| 2020 Q2 | 2.68 Billion USD | 2.25% |
| 2020 Q4 | 2.89 Billion USD | 6.92% |
| 2020 Q3 | 2.7 Billion USD | 0.71% |
| 2019 Q4 | 2.7 Billion USD | 2.0% |
| 2019 FY | 2.7 Billion USD | -13.2% |
| 2019 Q3 | 2.65 Billion USD | 0.34% |
| 2019 Q1 | 3.32 Billion USD | 6.62% |
| 2019 Q2 | 2.64 Billion USD | -20.45% |
| 2018 FY | 3.11 Billion USD | 29.05% |
| 2018 Q1 | 2.46 Billion USD | 2.32% |
| 2018 Q2 | 2.5 Billion USD | 1.26% |
| 2018 Q3 | 3.16 Billion USD | 26.6% |
| 2018 Q4 | 3.11 Billion USD | -1.61% |
| 2017 Q1 | 2.04 Billion USD | 1.52% |
| 2017 Q4 | 2.41 Billion USD | 10.13% |
| 2017 Q3 | 2.19 Billion USD | 2.24% |
| 2017 Q2 | 2.14 Billion USD | 5.0% |
| 2017 FY | 2.41 Billion USD | 20.03% |
| 2016 FY | 2.01 Billion USD | 9.31% |
| 2016 Q4 | 2.01 Billion USD | 5.36% |
| 2016 Q3 | 1.9 Billion USD | 3.41% |
| 2016 Q2 | 1.84 Billion USD | 7.1% |
| 2016 Q1 | 1.72 Billion USD | -6.33% |
| 2015 Q1 | 1.87 Billion USD | 0.06% |
| 2015 FY | 1.83 Billion USD | -1.89% |
| 2015 Q2 | 1.9 Billion USD | 1.78% |
| 2015 Q4 | 1.83 Billion USD | 2.35% |
| 2015 Q3 | 1.79 Billion USD | -5.88% |
| 2014 Q3 | 2 Billion USD | 2.52% |
| 2014 FY | 1.87 Billion USD | 26.17% |
| 2014 Q4 | 1.87 Billion USD | -6.45% |
| 2014 Q2 | 1.95 Billion USD | 32.07% |
| 2014 Q1 | 1.47 Billion USD | -0.39% |
| 2013 FY | 1.48 Billion USD | 19.1% |
| 2013 Q4 | 1.48 Billion USD | 2.95% |
| 2013 Q1 | 1.43 Billion USD | 14.82% |
| 2013 Q2 | 1.43 Billion USD | 0.16% |
| 2013 Q3 | 1.44 Billion USD | 0.6% |
| 2012 FY | 1.24 Billion USD | 11.32% |
| 2012 Q1 | 1.14 Billion USD | 1.85% |
| 2012 Q3 | 1.21 Billion USD | 4.09% |
| 2012 Q4 | 1.24 Billion USD | 2.61% |
| 2012 Q2 | 1.16 Billion USD | 2.34% |
| 2011 Q3 | 1.11 Billion USD | 2.1% |
| 2011 FY | 1.12 Billion USD | 74.71% |
| 2011 Q4 | 1.12 Billion USD | 0.82% |
| 2011 Q2 | 1.08 Billion USD | 2.81% |
| 2011 Q1 | 1.05 Billion USD | 65.09% |
| 2010 Q4 | 641.43 Million USD | 3.94% |
| 2010 FY | 641.43 Million USD | 13.39% |
| 2010 Q3 | 617.1 Million USD | 2.01% |
| 2010 Q1 | 563.41 Million USD | -0.4% |
| 2010 Q2 | 604.92 Million USD | 7.37% |
| 2009 Q4 | 565.68 Million USD | 4.84% |
| 2009 FY | 565.68 Million USD | 7.04% |
| 2009 Q1 | 517.43 Million USD | -2.09% |
| 2009 Q2 | 537.42 Million USD | 3.86% |
| 2009 Q3 | 539.59 Million USD | 0.4% |
| 2008 Q1 | 484.66 Million USD | -15.87% |
| 2008 Q3 | 508.32 Million USD | 1.48% |
| 2008 Q4 | 528.5 Million USD | 3.97% |
| 2008 FY | 528.5 Million USD | -8.25% |
| 2008 Q2 | 500.93 Million USD | 3.36% |
| 2007 Q3 | 488.95 Million USD | 0.45% |
| 2007 Q1 | 476.87 Million USD | 795.68% |
| 2007 FY | 576.05 Million USD | 981.95% |
| 2007 Q2 | 486.73 Million USD | 2.07% |
| 2007 Q4 | 576.05 Million USD | 17.81% |
| 2006 FY | 53.24 Million USD | 89.39% |
| 2006 Q2 | 44.28 Million USD | 31.0% |
| 2006 Q1 | 33.8 Million USD | 20.24% |
| 2006 Q3 | 45.4 Million USD | 2.53% |
| 2006 Q4 | 53.24 Million USD | 17.27% |
| 2005 Q2 | 20.97 Million USD | -1.82% |
| 2005 FY | 28.11 Million USD | 24.15% |
| 2005 Q4 | 28.11 Million USD | 8.45% |
| 2005 Q3 | 25.92 Million USD | 23.61% |
| 2005 Q1 | 21.35 Million USD | -5.68% |
| 2004 FY | 22.64 Million USD | -56.32% |
| 2004 Q3 | 23.34 Million USD | -58.02% |
| 2004 Q2 | 55.6 Million USD | 3.92% |
| 2004 Q4 | 22.64 Million USD | -2.99% |
| 2004 Q1 | 53.5 Million USD | 3.2% |
| 2003 Q3 | 55.21 Million USD | 9.05% |
| 2003 Q4 | 51.84 Million USD | -6.11% |
| 2003 FY | 51.84 Million USD | 3.36% |
| 2003 Q1 | 51.33 Million USD | 2.33% |
| 2003 Q2 | 50.63 Million USD | -1.36% |
| 2002 FY | 50.16 Million USD | 220.03% |
| 2002 Q1 | 41.42 Million USD | 164.27% |
| 2002 Q2 | 48.92 Million USD | 18.12% |
| 2002 Q3 | 49.77 Million USD | 1.73% |
| 2002 Q4 | 50.16 Million USD | 0.79% |
| 2001 Q1 | 9.44 Million USD | 8.67% |
| 2001 Q2 | 13.04 Million USD | 38.12% |
| 2001 Q4 | 15.67 Million USD | 12.46% |
| 2001 Q3 | 13.93 Million USD | 6.82% |
| 2001 FY | 15.67 Million USD | 80.31% |
| 2000 Q2 | 6.18 Million USD | 72.05% |
| 2000 Q4 | 8.69 Million USD | 6.61% |
| 2000 Q1 | 3.59 Million USD | 0.0% |
| 2000 Q3 | 8.15 Million USD | 31.8% |
| 2000 FY | 8.69 Million USD | 366.76% |
| 1999 FY | 1.86 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | -599.658% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -3362.359% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -606.809% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -1549.196% |
| bluebird bio, Inc. | 424.62 Million USD | -928.204% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -6249.714% |
| Imunon, Inc. | 8.53 Million USD | -51081.494% |
| Editas Medicine, Inc. | 150.05 Million USD | -2809.58% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 78.774% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | -24.547% |
| Myriad Genetics, Inc. | 312.9 Million USD | -1295.334% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | -328.291% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -795.661% |
| Verastem, Inc. | 71.18 Million USD | -6033.315% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 93.659% |
| Waters Corporation | 3.47 Billion USD | -25.586% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 91.585% |
| Biogen Inc. | 12.04 Billion USD | 63.754% |
| Nektar Therapeutics | 267.04 Million USD | -1534.924% |
| Perrigo Company plc | 6.04 Billion USD | 27.73% |
| Dynavax Technologies Corporation | 375.02 Million USD | -1064.192% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -12311.478% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -2130.533% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -1602.284% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -11607.605% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | -130.999% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -5196.423% |
| Evolus, Inc. | 209.68 Million USD | -1982.151% |
| Adicet Bio, Inc. | 37.12 Million USD | -11661.853% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -10753.677% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 38.568% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -560.724% |
| FibroGen, Inc. | 585.72 Million USD | -645.397% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 11.224% |
| OPKO Health, Inc. | 622.47 Million USD | -601.389% |
| Homology Medicines, Inc. | 118.53 Million USD | -3583.362% |
| Geron Corporation | 146.12 Million USD | -2887.812% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | -7.789% |
| Exelixis, Inc. | 678.44 Million USD | -543.53% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -21652.778% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -34733.254% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -1640.774% |
| Zoetis Inc. | 9.29 Billion USD | 53.029% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -999.031% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -8778.315% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 15.22% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -8912.282% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | -67.705% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | -81.52% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -3702.738% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | -164.692% |
| Blueprint Medicines Corporation | 918.64 Million USD | -375.267% |
| Insmed Incorporated | 1.66 Billion USD | -162.733% |
| TG Therapeutics, Inc. | 169.08 Million USD | -2482.133% |
| Incyte Corporation | 1.59 Billion USD | -174.2% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -268.252% |